Motif Bio Investors - MTFB

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Motif Bio Plc	MTFB	London	Ordinary Share	GB00BVVT4H71	ORD 0.01P

	Price Change	Price Change %	Stock Price	Last Trade
	0.00	0.0%	0.50	00:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
			0.50	0.50

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Date	Subject
20/1/2021 19:16	scottdavid70: As I have said there are only two possible reasons to run it this close: 1) That there is a imminent sale of Iclaprim that could provide upside to investors and that there were actually several companies wanting to do a deal with Motif and that it was so competitive it has taken this long to strike the right deal. If true, this would potentially create enormous value for shareholders whom came late top the party. Those invested on Lumsdens promises at +/- 30p are still going to be massively disappointed. Had they known liver experts had been on standby would probably have pulled their cash before Feb 14th. 2) Option 2 this is run. so close as to make investors feel that anything is better than nothing even if they get diluted to 10% of their current holding. Option 2 is my go to given what investors have had to deal with and see from this Board for 2 years now. I dont think it will delist and even if it does it maybe better than option 2 as we might still be able to get some upside from Iclaprim due to the contractual arrangement. RTO into a minnow we may lose that given how this Board has diluted and negotiated for us up to now Read Full Thread Follow Reply
14/1/2021 22:06	scottdavid70: While reminisce about Motif and the work Lumsdne did...by the way check out all the "fully deserved...well done Graham messages from his connections on Linklden. If you want to see herd immunity in terms of failing people congratulating more failure its there in all its glory. Incredible when they know what he has done to hard working investors money at Motif and failing to get Iclaprim approved they can all be congratulating him. Amazing. Anyway I digress - remember this pearler from 2nd September 2019? If you are in doubt about the total truth of the most recent update about a RTO look at this from the RNS: "We are well prepared for the meeting with the FDA on September 19 to discuss our proposed clinical trial for iclaprim. In addition, we are actively pursuing options to broaden our pipeline as we work to build shareholder value. We appreciate the continued support and flexibility of Hercules and the confidence that they have in our team to deliver on our strategic goals.” GL "Broaden our pipeline" Absolutely laughable stuff and the most outrageous lie of all time. For just 28 days later they were proposing the wind down of everything and becoming a cash shell and needed a cash raise!!!!! How were you planning to "Broaden the pipeline" Graham given that financial backdrop? What investors have had to endure here is beyond reasonable Read Full Thread Follow Reply
07/1/2021 13:13	scottdavid70: Greedy Gold and Graham only need to do a RTO to get their money. Lumsden an incredible BONUS of $100,000 and Gold $325,000 in deferred salary. If shareholders get sweet nothing they still get their money. Given there was zero Corporate Governance which continues with no communication from Motif then we can assume they will happily shaft investors who paid their lavish lifestyles. I would be hammering at their door asking for how a prospectus and vote can happen if investors are only getting an Update second half of the month. Smells v bad Read Full Thread Follow Reply
26/12/2020 10:50	scottdavid70: Contents for the “All Bases Covered” Graham Lumsden May 2019 Would include in the email Strict cost controls in 2019...$1.1 million US dollars to two Director’s is believed to have been paid? Is that the Definition of ‘strict cost controls?’ Where is the Lamellar update promised by Graham Lumsden in May 2019 for a few months later? What impact do the two new patents for Iclaprim approved this August for Sandoz have for Motif as it has a contract with Hercules? Obviously I am partial to the why does Lumsden have a Bonus of $100,000 if a RTO happens given it’s his incompetence that’s got us to this stage of basically being a month from being delisted? Having been diluted to oblivion did the Directors discuss working for free to show some empathy for the situation they have put investors in here who have lost nearly 95% of the value of their investment? Had they done so investors wounding be so significantly diluted? Also why was there no Board review as is good practice for Corporate Governance? Crowe also highlighted this inadequacy? Very irresponsible especially as new skill sets were needed for a cash shell looking for a RTO. Not the sort of skill set a former veterinarian Graham Lumsden possesses is it?? Take your pick and send the email on the 29th Dec at 7.30am Read Full Thread Follow Reply
25/12/2020 04:44	scottdavid70: Seasons Greeting and Happy Christmas to those that celebrate it to all the hard working ordinary investors here and there are many who have financed Graham Lumsden, Jon Gold, Bruce Williams and Chris Wardhaugh presents or celebrations. The same goes to Peel Hunt and Walbrook who have trousered so much of the investors monies to play their staff and in term allowed them to enjoy their Christmas indirectly benefitting from investors by making the Boards words seem believable. To the ordinary hard working people here I hope you can enjoy it and be safe in the knowledge that this will be the last Christmas you have to endure as a shareholder in this company. There will be no salvation here for investors and I hope in the long run not for the Board either for their reputations Read Full Thread Follow Reply
22/12/2020 20:43	scottdavid70: I goess the thing that is most central to my book is the theme of saying one thing and then it not happening such as: NDA submission late - one shot at goal? Or was it then that the liver issue was known that made them have liver experts on standby for the FDA? EMA submission in - quirky pulled with no RNS just slipped in a investor presentation Same with the HABP trials Then the no clinical trials Then the all bases covered Then the moving of the AGM to before the FDA decision Then the Iclaprim tie up with Lamellar and news in a few months - still nothing Full phase 3 trials and several years - huge funding and so reclassified as a shell company- vote needed otherwise company goes under - sound like all bases covered when on that type of knife edge? US Army trials announced to much fanfare - still nothing Strategic business partner for several Covid therapeutic companies- still no deal Fully funded till Feb 2021 - interims state significant dilution possible again for investors- why? Samdoz new patents for Iclaprim- we aren’t told anything Strict cost controls 2019 - almost US $1.1 million for two directors in 2019 Nasdaq needed for company to grow - sucked in too much cash for extra regulations - delist - vanity project for Graham most of us now think No Board reviews last year after a catastrophic year - why? Not good Corporate Governance Opaque RNS - several term sheets agreed yet still searching for a suitable a RTO. What exactly does that mean? The ones at Term Sheets aren’t good enough? Investors deserve better by their Directors than this mini resume of what’s gone on here Read Full Thread Follow Reply
18/12/2020 08:19	scottdavid70: So Motif got several offers to do a RTO due to companies wanting to get their COViD therapeutics to market. Motif then hire Peel Hunt who have failed over and over gain to realise value for investors despite making huge sums for themselves. Walbrook whom take hundred of thousands of pounds to not reply to investors. Were Peel Hunt brought in as they knew the skeletons? Why use the same company that has failed investors before with their predictions? Makes no sense? Why do Walbrook refuse to answer questions? Does anyone else smell a Graham here? Read Full Thread Follow Reply
17/12/2020 11:24	scottdavid70: For example, how are investors not emailing Motif and Walbrook to ask about the new patents this August for Iclaprim and Sandoz every day? Your investment could depend on what that means but they won’t mention it even happened. Yet they agree there is a contract in place that investors could benefit from via a sale so therefore it stands to reason that the investors here who have been shafted by the Board to date should be informed of the potential upside these patents mean Read Full Thread Follow Reply
10/12/2020 08:37	scottdavid70: When is Laureate Lumsdens next appearance on ProActive Investors? I miss his prose and utter hogwash. We are still waiting 18 months after he said the tie up with Lamellar would have some findings ready for investors a few months after signing in May 2019. Utterly shambolic Read Full Thread Follow Reply
24/10/2020 19:06	scottdavid70: No investors are going to touch Directors who also attempted to disapply pre-emption rights WITHOUT engaging in conversations with investors to explain and outline why that is the right course of action. By not ENGAGING AT ALL it certainly felt that it wasn’t in any of the investors best interests otherwise a explanation would have been forthcoming before or even after. NONE HAS BEEN TOTAL RADIO SILENCE Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

MTFB

Motif Bio

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20210125 20:31:36